Novavax (NVAX) Tops Q2 EPS by 68c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Price: $8.73 -2.35%
Financial Fact:
Research and development: 52.98M
Today's EPS Names:
XYF, SQZB, RENO, More
Financial Fact:
Research and development: 52.98M
Today's EPS Names:
XYF, SQZB, RENO, More
Join SI Premium – FREE
Novavax (NASDAQ: NVAX) reported Q2 EPS of $0.62, $0.68 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $239 million versus the consensus estimate of $156.23 million.
GUIDANCE:
Novavax sees Q3 2025 revenue of $495-545 million, versus the consensus of $89.61 million.
Novavax sees FY2025 revenue of $1-1.05 billion, versus the consensus of $1.02 billion.
For earnings history and earnings-related data on Novavax (NVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bessent: U.S. will enforce 'zero leakage' approach to Iran sanctions
- Bessent: I expect a major financial institution to be sanctioned this week
- Broadcom credit risk measures rise amid AI financing deals
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
